Ascendis Pharma Endocrinology Division A/s

Ascendis Pharma Endocrinology Division

Steen Jensen

Harald Rau

Thomas Wegge

Joachim Zettler

Torben Lessmann

Grethe Nørskov Rasmussen

Alina Hermann

Nina Schubert

Evelyn Exner

Thomas Kurpiers

Kennett Sprogøe

Henrik Egesborg

Anna Splanemann

Kennett SprogØe

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Polymeric hGH prodrugs

The present invention relates a pharmaceutical formulation comprising a long-acting growth hormone for use in a method of treating growth hormone deficiency, wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, to a multitude of unit dosage forms comprising a long-acting growth hormone formulation, wherein the unit dosage forms comprise increasing amounts of growth hormone equivalents and wherein the amount of growth hormone equivalents increases by at least 10% between one unit dosage form and the next higher dosage form; their use in a method of treating growth hormone deficiency and method of treating growth hormone deficiency in a bracketed dosing regimen.

Long-acting growth hormone treatment

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

Growing community of inventors

Dragoer, Denmark

Steen Jensen